If you would like to ask our webinar guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund a question please submit them here.

 

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,772.50
Bid: 1,772.00
Ask: 1,772.50
Change: 11.50 (0.65%)
Spread: 0.50 (0.028%)
Open: 1,770.00
High: 1,776.00
Low: 1,766.00
Prev. Close: 1,761.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Wednesday preview: Glaxo, MPC minutes, US CPI all due out

Tue, 21st Oct 2014 15:11

Glaxosmithklline will be among the most high-profile companies to release results on Wendesday as the pharmaceutical giant reports its third-quarter figures.The drugmaker is expected to deliver sales of £5.74bn in the three months to 30 September, down from £6.51bn in the third quarter of 2013.The consensus forecast is for core operating profit is £1.71bn, compared with £2.06bn a year earlier.Glaxo said at the time of its half-year report in July that good progress made with its newly-launched products was being offset by pricing and contracting pressures in the US, with sale declines of its asthma and COPD treatment Advair in particular likely to continue."Double-digit volume declines [of Advair] are still the norm and pricing will likely get worse before it gets better," said analyst Savvas Neophytou from Panmure Gordon, who estimated that Advair contributes around 25% of group profits.In Britain focus will be on the minutes from the Monetary Policy Committee's last rate setting meeting, That comes as over the last few weeks markets have pushed out the expected date of a first increase in Bank Rate to the third quarter of 2015.Stateside all eyes will be on the latest consumer price figures, for the month of September. Barclays Research expects the headline US consumer price index to fall by 0.5 percentage points in the last quarter of the year in seasonally adjusted annualised terms, providing a net boost to the country's rate of GDP growth worth 0.4 percentage points.Wednesday October 22 INTERIMS Development Securities, Home Retail Group INTERNATIONAL ECONOMIC ANNOUNCEMENTS Consumer Price Index (US) (13:30) Crude Oil Inventories (US) (15:30) MBA Mortgage Applications (US) (12:00) Q3GlaxoSmithKline, Nord Gold NV GDR (Reg S), Norsk Hydro ASA, Orange Polska S.A. GDR (Reg S) FINALS Spirit Pub Company, Xeros Technology Group ANNUAL REPORT Kirkland Lake Gold Inc. IMSS British American Tobacco, Computacenter, International Personal Finance, Laird, Playtech, Senior EGMS Global Ports Investments GDR (REG S) AGMS FinnAust Mining, Ingenious Media Active Capital Ltd., Kirkland Lake Gold Inc. TRADING ANNOUNCEMENTS Playtech, Plus500 Ltd (DI) UK ECONOMIC ANNOUNCEMENTS BoE Interest Rate Minutes (09:30) FINAL DIVIDEND PAYMENT DATE Rank Group
More News
17 Jan 2024 07:46

LONDON BRIEFING: UK inflation surprises as unexpectedly rises to 4.0%

(Alliance News) - Stocks in London are called to open lower on Wednesday, following some hotter-than-expected consumer price data from the UK.

Read more
17 Jan 2024 07:31

GSK raises $1.24 bln from latest Haleon stake sale

Jan 17 (Reuters) - GSK has raised 978 million pounds ($1.24 billion) from a discounted sale of a stake in its spun-off consumer healthcare business Haleon, the British drugmaker said on Wednesday.

Read more
16 Jan 2024 17:04

GSK to sell GBP1 billion worth of Haleon shares as trims stake again

(Alliance News) - GSK PLC on Tuesday said it intends to sell around GBP1.00 billion worth of shares in Haleon PLC, as it continues to reduce its shareholding in the Weybridge, Surrey-based consumer healthcare spin-off.

Read more
16 Jan 2024 09:14

LONDON BROKER RATINGS: UBS raises GSK and cuts AstraZeneca

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
16 Jan 2024 08:15

UBS downgrades AstraZeneca to 'sell'

(Sharecast News) - UBS has downgraded AstraZeneca and upgraded rival GSK as part of its latest review of the European pharmaceutical sector.

Read more
16 Jan 2024 07:37

LONDON BRIEFING: UK jobless rate sticks at 4.2% but pay growth slows

(Alliance News) - Stocks in London are called to open lower on Tuesday, following data showing that the UK jobless rate was unchanged at 4.2% as pay growth slowed.

Read more
15 Jan 2024 08:42

Zantac fallout unfairly weighing on GSK, says Shore Capital

(Sharecast News) - Shore Capital has raised its target price and maintained a positive stance on biopharma giant GSK, saying that worries about the potential cost of Zantac litigation are unfairly weighing on the stock.

Read more
10 Jan 2024 09:35

LONDON BROKER RATINGS: BofA cuts Ashtead; UBS likes 3i Group

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
10 Jan 2024 08:25

GSK says Nucala gets green light in China for asthma treatment

(Alliance News) - GSK PLC on Wednesday said Nucala has been approved in China for the treatment of severe asthma.

Read more
10 Jan 2024 07:22

GSK's Nucala gets fresh approval in China

(Sharecast News) - GSK announced on Wednesday that the China National Medical Products Administration (NMPA) has granted approval for 'Nucala', or mepolizumab, as an add-on maintenance treatment for severe eosinophilic asthma in adults and adolescents aged 12 years and older.

Read more
9 Jan 2024 16:22

London close: Stocks finish red after choppy session

(Sharecast News) - London stocks had turned back into the red by the close on Tuesday, with recruitment firms and asset managers pacing the declines after some disappointing corporate updates.

Read more
9 Jan 2024 08:03

TOP NEWS: GSK to buy Aiolos Bio for up to USD1.4 billion

(Alliance News) - GSK PLC on Tuesday said it will acquire asthma drug developer Aiolos Bio Inc for USD1 billion upfront, as well as up to USD400 million in certain success-based milestone payments.

Read more
9 Jan 2024 07:16

GSK buys respiratory drug maker Aiolos for $1bn

(Sharecast News) - GSK said it was buying Aiolos, a clinical-stage biopharmaceutical company focused on treatment of respiratory and inflammatory conditions, for up to $1.4bn (£1.1bn).

Read more
8 Jan 2024 23:39

Pfizer to remain aggressive on obesity market after setback

NEW YORK, Jan 8 (Reuters) - Pfizer will remain aggressive in trying to break into the lucrative obesity market, even after dropping a high profile weight-loss drug candidate late last year due to strong side effects, Chief Executive Albert Bourla said on Monday.

Read more
8 Jan 2024 23:00

Pfizer to remain aggressive on obesity market after setback

NEW YORK, Jan 8 (Reuters) - Pfizer will remain aggressive in trying to break into the lucrative obesity market, even after dropping a high profile weight-loss drug candidate late last year due to strong side effects, Chief Executive Albert Bourla said on Monday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.